← Trials/Trial dossier/NCT06937060

SEMPSO

RecruitingPhase 3

Effect of Semaglutide in Patients With Psoriasis and Obesity

Lead sponsor

The University of Hong Kong

Asset

Semaglutide

GLP-1 agonist

Listed sites

Recruiting sites

Enrollment

estimated

Study population

Obesity / overweight, Psoriasis / psoriatic arthritis

Key I/E criterion

—

Primary endpoint

•Mean Psoriasis Area and Severity Index (PASI) before

Footprint

Where this trial recruits

Site locations as reported to ClinicalTrials.gov. Site count is not enrollment count; per-site enrollment is not available from source.

Identifiers

Registered as

NCT IDNCT06937060

Org study IDUW 25-083

Timeline

Milestones

Study start2025-03-20actual

Study first posted2025-04-20actual

Last update posted2025-05-13actual

Primary completion2026-07-31estimated

Study completion2027-01-31estimated

Assets

Investigational agents

Semaglutide

Study populations

Who this study enrolls

Obesity / overweightPsoriasis / psoriatic arthritis

Eligibility

Who can enroll

Minimum age18 Years

Maximum age75 Years

SexAll

Healthy volunteersNot accepted

Inclusion criteria

•a clinical diagnosed Psoriatic disease of at least 6 months before signing of informed consent.

•Women who are sexually active and not postmenopausal, agreement to remain abstinent or use 2 effective methods of contraception

•>18 years of age, up to 75 years of age

•Adult with an initial body mass index (BMI) of 30 kg/m2 or greater (obesity) or 27 kg/m2 or greater (overweight) in the presence of at least one weight-related comorbid condition (e.g., hypertension, type 2 diabetes mellitus, or dyslipidemia)

•Moderate to severe psoriasis (PASI score 5-10= moderate, >10 = severe)

•Chinese ethnicity

•On stable dose of standard treatment

•Ability to comply with stud

Exclusion criteria

•Patients who refuse to give consent

•Contraindication to use of GLP1 RA

•History of pancreatitis

•History of MEN / MTC

•Known hypersensitivity to semaglutide or excipients in semaglutide

•Type 1 diabetes

•Gallbladder disease

•Active malignancy or History of malignancy within 5 years

•Active chronic or acute infection requiring treatment with systemic antibiotics, antiviral, antiparasitic, antiprotozoal, or antifungals within 4 weeks before baseline visit

•Pregnancy or breastfeeding, subjects should inform their healthcare provider of a known or suspected pregnancy

•History of allergic reaction assessed as related to investigational product by the investigator

•Major psychiatric illness

•Treatment with live/ attenuated vaccine within the last 28 days prior to randomisation

•History of alcohol or substance abuse within 6 months prior to initial screening

•Patients with a history of suicidal attempts or active suicidal ideation

Endpoints (1)

What's being measured

Protocol endpoints and posted registry outcome measures, grouped into outcome categories. Composite endpoints show their component event types. Standard codes (LOINC, SNOMED CT) are shown where available.

Other clinical outcomes

1 endpoint

Primary/protocol endpoint

Change in mean Psoriasis Area and Severity Index (PASI) before and after semaglutide treatment.

Time frame:36 weeks

change from baseline, improvement

Provenance

Sources

Trial identity, design, statusClinicalTrials.gov API v2

Snapshot dateJuly 1, 2026

Endpoint classificationDelfa endpoint taxonomy v2 (May 13, 2026)

Results tableno registry results posted yet

Trial facts come from public ClinicalTrials.gov records. Endpoint categories are Delfa's classification of those records, not a ClinicalTrials.gov field. All figures reflect the July 1, 2026 snapshot.